Bristol-Myers Again Urges Justices To Assess Hepatitis Patent
Bristol-Myers Squibb Co. has urged the U.S. Supreme Court to reject an opposition by Teva Pharmaceuticals USA Inc. and review a Federal Circuit's decision to invalidate a patent on hepatitis B...To view the full article, register now.
Already a subscriber? Click here to view full article